Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

28.52
+0.44001.57%
Post-market: 28.00-0.5200-1.82%19:30 EDT
Volume:848.79K
Turnover:24.39M
Market Cap:3.24B
PE:-11.48
High:29.30
Open:28.46
Low:28.13
Close:28.08
52wk High:30.06
52wk Low:8.67
Shares:113.58M
Float Shares:108.11M
Volume Ratio:0.61
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4851
EPS(LYR):-2.4315
ROE:-64.03%
ROA:-37.78%
PB:6.17
PE(LYR):-11.73

Loading ...

Piper Sandler Keeps Their Buy Rating on Immunome (IMNM)

TIPRANKS
·
Aug 12

Simris Alg Q2 Ebitda Loss Narrows

Reuters
·
Aug 12

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 12

Oncology Firm Immunome's Q2 Net Loss Widens as R&D Costs Rise

Reuters
·
Aug 12

Immunome Q2 EPS $(0.65) Misses $(0.52) Estimate

Benzinga Earnings
·
Aug 12

Immunome Rugi Bersih Q2 FY26 Melebar Ke USD 73,13 Juta; Revenue Tidak Ada

Reuters
·
Aug 12

Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 12

Immunome Director Isaac Barchas Reports Disposal of 36,088 Common Shares Worth $940,453.28

Reuters
·
Aug 11

Immunome, Inc. Expected to Post a Loss of 52 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Immunome Chief Business Officer Horn Kinney Sells 90,616 Common Shares for $2.27 Million

Reuters
·
Aug 07

Immunome Grants Inducement Stock Options for 176,500 Shares at $23.01 to New Hires

Reuters
·
Aug 07

Immunome Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 07

Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Argenx Se (ARGX)

TIPRANKS
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Immunome (IMNM) and Incyte (INCY)

TIPRANKS
·
Jul 22

Immunome Price Target Maintained with a $31.00/share by Wedbush

Dow Jones
·
Jul 21

Immunome Begins Phase 1 Trial Dosing of Therapy for Advanced Solid Tumors

MT Newswires Live
·
Jul 20

Immunome announces first patient dosed in Phase 1 IM-3050 trial

TIPRANKS
·
Jul 20

Immunome Notifies Availability of Press Release

Reuters
·
Jul 20

Immunome - Phase 1 Trial to Evaluate Safety and Preliminary Activity of Im-3050

THOMSON REUTERS
·
Jul 20

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating Im-3050, an Fap-targeted Radioligand Therapy, in Patients with Fap-expressing Advanced Solid Tumors

THOMSON REUTERS
·
Jul 20